Journal of Preventive Veterinary Medicine

The Korean Society of Preventive Veterinary Medicine (한국예방수의학회)
권호 표지
DOI QR코드

DOI QR Code

Immunization with Brucella abortus recombinant proteins protects BALB/c mice from Brucella abortus 544 infection

  • Arayan, Lauren Togonon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Tran, Xuan Ngoc Huy (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Reyes, Alisha Wehdnesday Bernardo (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Huynh, Tan Hop (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Vu, Hai Son (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Min, WonGi (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Lee, Hu Jang (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Kim, Suk (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
  • Received : 2018.09.13
  • Accepted : 2018.11.25
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

This study evaluated the protective effects of a combination of eight B. abortus recombinant proteins that were cloned and expressed into a pMal vector system and $DH5{\alpha}$: nucleoside diphosphate kinase (rNdk), 50S ribosomal protein (rL7/L12), malate dehydrogenase (rMDH), DNA starvation/stationary phase protection protein (rDps), elongation factor (rTsf), arginase (rRocF), superoxide dismutase (rSodC), and riboflavin synthase subunit beta (rRibH). The proteins were induced, purified, and administered intraperitoneally into BALB/c mice. The mice were immunized three times at weeks 0, 2, and 5 and then infected intraperitoneally (IP) with $5{\times}10^4CFU$ of virulent B. abortus 544 one week after the last immunization. The spleens were collected and the bacterial burden was evaluated at four weeks post-infection. The results showed that this combination produced a significant reduction of the bacterial burden in the spleen with a log reduction of 1.01 compared to the PBS group. Cytokine analysis revealed induction of the cell-mediated immune response in that TNF (tumor necrosis factor) and proinflammatory cytokines IL-6 (Interleukin 6) and MCP-1 (macrophage chemoattractant protein-1) were elevated significantly. In summary, vaccination with a combination of eight different proteins induced a significant protective effect indicative of a cell mediated immune response.

Keywords

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI)

References

  1. Avila-Calderon ED, Lopez-Merino A, Sriranganathan N, Boyle SM, Contreras- Rodriguez A. A history of the development of Brucella vaccines. Biomed Res Int. 2013, 2013:743509.
  2. Baldwin CL, Jiang X, Fernandez DM. Macrophage control of Brucella abortus: influence of cytokines and iron. Trends Microbiol. 1993, 1: 99-104. https://doi.org/10.1016/0966-842X(93)90115-8
  3. Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 1997, 3: 213-221. https://doi.org/10.3201/eid0302.970219
  4. Dubray G, Bezard G. Isolation of three Brucella abortus cell wall antigens protective in murine experimental brucellosis. Ann Rech Vet. 1980, 11: 367-373.
  5. Hop HT, Arayan LT, Tran Xuan H, Reyes AW B, Kim S. Immunization of BALB/c mice with a combination of four recombinant Brucella abortus proteins, AspC, Dps, InpB and Ndk, confers a marked protection against a virulent strain of Brucella abortus. Vaccine. 2018, 36: 3027-3033. https://doi.org/10.1016/j.vaccine.2018.04.019
  6. Hop HT, Simborio HL, Reyes A, Arayan LT, Min W. Immunogenicity and protective effect of recombinant Brucella abortus Ndk (rNdk) against a virulent strain Brucella abortus 544 infection in BALB/c mice. FEMS Microbiol Lett. 2015, 362: 1-6.
  7. Im YB, Park WB, Jung M, Kim S, Yoo HS. Evaluation of Th1/Th2-Related immune response against recombinant proteins of Brucella abortus infection in mice. J Microbiol Biotechnol. 2016, 26:1132-1139. https://doi.org/10.4014/jmb.1512.12046
  8. Lim JJ, Kim DH, Kim DG. Protective effects of recombinant Brucella abortus Omp28 against infection with a virulent strain of Brucella abortus 544 in mice. Vet Sci. 2012, 13: 287-292. https://doi.org/10.4142/jvs.2012.13.3.287
  9. Martirosvan A, Von Bargen A, Arce-Gorvel V, Zhao W, Hanniffy S, Bonnardel J. In vivo identification and characterization of CD4+ cytotoxic T cells. PLoS One. 2013, 19:e82508.
  10. Moriyon I, Grillo MJ, Monreal D, Gonzales D, Marin C, Lopez-Goni I, Mainar-Jaim RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004, 35: 1-38. https://doi.org/10.1051/vetres:2003037
  11. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunol. 2001, 103: 511-8. https://doi.org/10.1046/j.1365-2567.2001.01258.x
  12. Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996, 14: 959-962. https://doi.org/10.1016/0264-410X(96)00018-7
  13. Perkins S, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010, 34: 379-394. https://doi.org/10.1111/j.1574-6976.2010.00211.x
  14. Reyes AWB, Simborio HLT, Huyhn TH , Arayan LT, Kim S. Molecular cloning, purification and immunogenicity of recombinant Brucella abortus 544 malate dehydrogenase protein. J Vet Sci. 2016, 17:119-122. https://doi.org/10.4142/jvs.2016.17.1.119
  15. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol. 2002, 90: 479-496. https://doi.org/10.1016/S0378-1135(02)00255-9
  16. Skendros P, Boura P. Immunity to brucellosis. Rev Sci Tech. 2013, 32:137-147. https://doi.org/10.20506/rst.32.1.2190
  17. Velikovsky CA, Goldbaum FA, Cassataro J. Estein S, Bowden RA, Bruno L, Fossati CA, Giambartolome GH. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect Immun. 2003, 71: 5750-5755. https://doi.org/10.1128/IAI.71.10.5750-5755.2003